Appeals panel backs dismissal of AZ, Bristol-Myers kickback suit; Reckitt sales slow as pharma spinoff nears;

@FiercePharma: Can't stop gambling or shopping? Parkinson's meds may be to blame, JAMA study finds. Feature | Follow @FiercePharma

@EricPFierce: RT @FiercePharma: Top-read special report Monday: The top 10 most expensive drugs of 2013. Report | Follow @EricPFierce

@CarlyHFierce: Novartis recruits Nick Cannon for double-whammy flu campaign. FiercePharmaMarketing story | Follow @CarlyHFierce

> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) won't have to fight a whistleblower lawsuit over alleged kickbacks to a pharma benefits manager; a U.S. appeals court upheld a lower court's decision to toss the case. Report

> The U.K.'s Reckitt Benckiser saw sales growth slow in the third quarter as it prepares to spin off its pharma business by the end of this year. Report

> An epilepsy patient group is urging Congress to pass new Drug Enforcement Administration scheduling rules to speed up access to drugs for the condition. Release

> Johnson & Johnson ($JNJ) and its partner Pharmacyclics ($PCYC) asked the FDA to approve a new use for their cancer drug Imbruvica, in patients with Waldenström's macroglobulinemia. Release

> Novartis ($NVS) sued India's Dr. Reddy's Laboratories over the latter's filing for U.S. approval for a version of its blood cancer drug Gleevec. Report

> Bayer's new pulmonary arterial hypertension drug Adempas won a Prix Galien award, which recognizes achievements in pharma science. Release

Medical Device News

@FierceMedDev: 2014's most memorable medtech patent battles. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Nanodevices could be unleashed by DNA-brick self-assembly. Article | Follow @VarunSaxena2

@EmilyWFierce: RIP Shabbvie. Bloomberg piece | Follow @EmilyWFierce

> Illumina up 10% on strongest growth since 2011, raises 2014 guidance. Story

> Google, KKR, Kleiner Perkins invest $542M in virtual reality eyeglass startup. Article

> FDA clears app to monitor brain health on the battlefield. More

> Q&A: CMO says Covidien wants to engage parallel review process. Editor's Corner

Biotech News

@FierceBiotech: Great panel with $BLUE, $PFE, $AGIO, $GSK and $SNY on the revolution in drug R&D. Video will be up on site tomorrow. | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: RT @DatamonitorMark: David Shlaes: "AZ has told its antibiotics researchers they should make efforts to find other jobs in near future." Blog post via Antibiotics - The Perfect Storm | Follow @DamianFierce

@EmilyMFierce: Human intestinal organoids grown in mice could help personalize treatments. FierceBiotech Research story | Follow @EmilyMFierce

> AbbVie's $55B deal for Shire is officially dead. Now what? More

> Omeros halts a Phase II Huntington's trial over alarming rat results. Story

> Despite a mid-stage miss, Cytokinetics is taking its ALS drug toward Phase III. Article

Biotech Research News

> GlaxoSmithKline drug flips off cancer mechanism in aggressive leukemia. Story

> Protein boost restores hearing in deaf mice. More

> Human intestinal organoids grown in mice could help personalize treatments. Story

> Researchers pinpoint potent anti-obesity compounds. More

> Protein switch could boost recovery after heart attack. Article

Pharma Manufacturing News

> Janssen recalls 13,500 bottles of Xarelto because of contamination. News

> Canada cuts Apotex a break on some banned drugs. Report

> BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug. Article

> FDA will start the new year with its Office of Quality in place. Item

> Lilly closing a Puerto Rico plant next year but investing in another. More

And Finally... The U.K. government has backed access to unapproved meds for terminally ill patients. Report

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.